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Introduction
Brachytherapy (derived from the Greek term brachios, mean-
ing short) is defined as the treatment of tumors through the
placement of radioactive sources into or close to the malignant
lesion. The main advantage of brachytherapy is based on the
inverse squared law inherent to radioactive sources, which
allows the delivery of a very high dose of radiation to the
tumor with a substantial sparing of the surrounding normal
tissues.
Historically, brachytherapy has evolved from hot loading
(i.e. manual placement of radioactive devices into the patient)
to remote afterloading. In remote afterloading, non-radioactive
applicators are inserted into the tumor; these applicators are
then loaded using mechanically driven, computer-controlled
equipment after dosimetry is approved. From the radiation
safety standpoint, remote afterloading eliminates the radiation
hazards for both the hospital staff and visitors, and allows
more convenient access to the patient.
Brachytherapy techniques, largely obscured with the
advancement of modern teletherapy equipment after 1960,
have received increasing attention over the last 15 years. The
reasons that have contributed to this brachytherapy renais-
sance are multiple.
(i) Advances in brachytherapy software, particularly the
integration of computed tomography (CT) image acquisition
and computer-driven dosimetry, now allow a fast and meticu-
lous analysis of the area to be treated with brachytherapy. The
spatial relationship between the radiation isodoses and the
volumes of interest is now visualized in a three-dimensional
environment and displayed through dose volume histograms.
Similarly, small imperfections in the implant quality can be
corrected by changing the dwell times of the multistepping
sources used in modern brachytherapy. As a result, tumor cov-
erage is improved, and radiation dose to critical organs
minimized.
(ii) Brachytherapy equipment has been improved with the
design of small, stepping flexible sources with high specific
activity (192Ir) that can navigate through thin plastic or metal
applicators of up to 5 French in diameter (1.5mm). These
sources can be designed to deliver treatments at a high dose
rate (>12Gy/h) that substantially shortens the period for
which the patient remains radioactive.
(iii) Low-energy, low-activity gamma radionuclides (125I,
103Pd) are now available and can be used in permanent
implants. These sources present a negligible radiological
hazard when used for deep-seated tumors. Permanent implants
have the advantage of requiring a much shorter hospital stay
than other types of radiation therapy, and they are perceived
by the patient as a less aggressive and more convenient type
of therapy.
(iv) Finally, developments in medicine and health education
have increased the number of patients with malignant tumors
who are diagnosed at an earlier stage. As a result, many
patients now present with small tumors that have a high prob-
ability of being organ-confined and that may be treated with
organ therapies, such as brachytherapy.
Clinical indications for brachytherapy have expanded. Apart
from the classical disease situations where the use of bra-
chytherapy is undebatable, as in gynecological cancer [1], new
malignant tumors are now increasingly being treated with this
treatment modality. In the USA, the number of patients with
low-risk prostate cancer treated with permanent brachytherapy
implants [2] is almost equal to the number treated with sur-
gery or external beam radiotherapy (EBRT), the two main
standard approaches in the past. In moderate and high-risk
prostate cancer, brachytherapy is also increasingly combined
with EBRT to escalate the total dose delivered to the tumor, a
treatment strategy which has proven superior over low-dose
therapy [3]. Brachytherapy is also increasingly being used as
the sole treatment modality for low-risk breast cancer.
Although this approach is still experimental, initial results
published worldwide report efficacy similar to standard EBRT
with the advantage of reducing treatment time from 6 weeks
to only 5 days [4]. Brachytherapy also plays an important role
in the treatment of skin cancer [5], pediatric malignancies [6],
and malignant obstruction due to lung [7], esophageal [8] and
biliary duct cancer [9].
Finally, brachytherapy has been used in combination with
surgical resection in the treatment of tumors that cannot be
removed with wide margins. These patients are at a very high
risk of relapse and usually need additional treatment with
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radiation therapy. This approach, using low-dose rate perio-
perative brachytherapy, has been applied extensively in the
management of soft tissue sarcomas [10], but has potential for
treating other tumor sites. However, the use of perioperative
brachytherapy with modern high-dose rate technology remains
largely unexplored. The techniques and results obtained at the
University of Navarre with perioperative high-dose rate bra-
chytherapy (PHDRB) are presented herein.
Perioperative high dose rate brachytherapy
In February 2000, we initiated a prospective, non-randomized,
controlled (phase I or II) clinical study to determine whether
PHDRB administered over the immediate postoperative period
was useful to: (ii) safely escalate the radiation dose in well-
defined areas of the surgical field that displayed high-risk fea-
tures; and (ii) shorten the overall treatment time.
The successful protocol accrual, with more than 190
patients treated so far, is largely attributable to the pioneering
work of Dr Calvo and colleagues with intraoperative electron
beam radiotherapy at the University of Navarra. This prior
experience allowed us to establish a close and friendly coop-
erative relationship with the different surgical teams involved
in surgical oncology who were ready to face the challenges of
a relatively new and unexplored treatment modality (Table 1).
Intraoperative implantation of plastic catheters into the
tumor bed after surgical resection for PHDRB has several
theoretical advantages over other types of radiation boosting
techniques, including:
(i) accurate real-time definition of the clinical target
volume (CTV) [11] surrounding the tumor bed and other high-
risk areas (with the assistance of the surgical team);
(ii) CT scan-based treatment planning;
(iii) risk-adapted brachytherapy dose selection based upon
the amount of residual disease described in the final pathology
report; and
(iv) early delivery of fractionated radiation during the
immediate postoperative period.
Materials and methods
Eligibility criteria
In general, any patient who, after preliminary evaluation, was considered
a candidate for combined modality treatment with surgery and high-dose
radiotherapy received a full explanation of the potential advantages of
the PHDRB protocol as well as its investigational nature. Informed con-
sent was required before study entry.
PHDRB protocol
Irradiation naı¨ve patients. Unirradiated patients were treated with surgical
resection and implantation of catheters for PHDRB. The brachytherapy
dose was divided into three different levels according to the presumed
amount of residual disease left as described in the final pathology report,
usually available within 48 h after surgery. In R0 resections, the surgical
margins were >_10mm. In R1 resections, surgical margins were either
close (<10mm) or microscopically positive, or extracapsular nodal exten-
sion was present. In R2 resections, gross residual disease was present.
R0 resections: brachytherapy dose = 4Gy twice daily 4 (16Gy total
dose)
R1 resections: brachytherapy dose = 4Gy twice daily 6 (24Gy total
dose)
R2 resections: brachytherapy dose = 4Gy twice daily 8 (32Gy total
dose)
Radiation treatment was completed with 45Gy of EBRT in 25 treat-
ments, 1.8Gy daily fractions, 4–5 weeks after the surgical procedure.
Total radiation doses equivalent to standard fractionation regimens deliv-
ered with 2Gy daily fractions and calculated with the linear quadratic for-
mulation [12] without time correction {i.e. BED= nd[1 + d/(a /b)]} are
shown in Figure 1).
Concomitant chemotherapy, if indicated, was added during the first and
fifth weeks of EBRT.
Previously irradiated patients. Patients with recurrent disease after prior
irradiation or patients with primary cancer arising in a previously irra-
diated field were treated with surgical resection and PHDRB. The bra-
chytherapy dose was divided into three different dose levels according to
the amount of residual disease present in the surgical bed as described in
the final pathology report:
R0 resections: brachytherapy dose = 4Gy twice daily 8 (32Gy total
dose)
R1 resections: brachytherapy dose = 4Gy twice daily 10 (40Gy total
dose)
R2 resections: brachytherapy dose = 4Gy twice daily 12 (48Gy total
dose)
Further EBRT was not administered.
Intraoperative target definition
The surgical and the radiation oncology teams used the preoperative
physical and imaging, surgical findings, frozen sections where necessary,
and gross examination of the surgical specimen to jointly determine the
area to be implanted.
Head and neck surgery. The CTV was all surgical field areas presumed to
belong to Radiation Therapy Oncology Group (RTOG) risk category 2
Table 1. Prior perioperative high dose rate brachytherapy reports
Author Institution Journal and Year n Comments
Ho¨ckel et al. [17] Mainz, Germany Cancer 1996 48 Gynecologic
Hannoun-Levi et al. [20] Marseille, France Eur J Surg Oncol 1997 14 Pelvic
Kwiatkowski et al. [21] Stuttgart, Germany Anticancer Res 1999 60 Case mix
Krull et al. [22] Hamburg, Germany Anticancer Res 1999 9 Head and neck cancer
Koizumi et al. [23] Osaka, Japan Int J Radiat Oncol Biol Phys 1999 16 Sarcomas
Petera et al. [24] Czech Republic Neoplasma 2004 21 Sarcomas
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(i.e. two or more positive nodes or extracapsular nodal extension with
negative margins) or risk category 3 (positive margins) [13] (Figure 2).
In practice, the implanted area covered the CTV around the primary
tumor and the lymphatic chains with nodes >2–3 cm in diameter, which
have a substantial probability of extracapsular extension [14].
Gynecological surgery. The CTV was all surgical field areas of tumor or
nodal adherence to the pelvic wall(s) or lumboaortic vessels. No attempt
was made to implant nodal areas at risk but clinically negative (Figure 3).
In practice, the implanted area covered the entire pelvic sidewall from
the lower paravaginal space (obturator fossa) to the promontorium in pel-
vic locations or the lumboaortic area in paraortic nodal relapses.
Sarcoma surgery. The CTV was the entire surgical bed.
Brachytherapy technique
The CTV was covered with a set of plastic catheters placed as parallel as
possible at 1–1.5 cm intervals with a margin of 1 cm in all directions. The
lateral margins were provided with additional catheters extending beyond
the CTV. Catheters were inserted no more than 5mm deep into the tumor
bed to avoid underdosage of the surgical surface. This maneuver avoids
catheter displacement and results in an improved geometry. Furthermore,
the surgical surface remains catheter-free, making surgical reconstruction
easier. In cases in which the catheters could not be inserted below the sur-
face, reabsorbable sutures were used to secure the catheters onto the surgi-
cal plane. In addition, catheters were attached at the skin exit points with
plastic buttons and silk sutures. The American Brachytherapy Society rec-
ommendations for brachytherapy implants in soft tissue sarcomas [15]
were generally followed to develop the individual techniques for other
anatomical areas. Some characteristics of individual procedures include
the following.
Head and neck surgery. Single-plane implants were the preferred tech-
nique for both the primary tumor bed and the neck. In this location, the
longitudinal margins were covered by setting the blind end of the catheters
at 1–1.5 cm above the mucosal surface with the aid of a plastic spacer
using a non-looping technique described previously [16]. Once the implant
was completed, immediate reconstruction of the surgical defect was per-
formed, if necessary, with regional flaps (infrahyoid and pectoralis major
myocutaneous flaps) or microvascular free flaps including radial flap, lat-
eral arm flap, abdominis flap and fibula.
Gynecological surgery. Single-plane implants were the preferred tech-
nique. The abdominal approach was used in the first five patients but was
abandoned afterwards due to the interference of the pubic arch with the
placement of catheters in low-lying tumors. In addition, in one patient a
catheter became dislocated and the treatment had to be aborted. For that
reason, from the sixth patient onwards, we used the perineal approach
with passage of percutaneous catheters through the paravaginal or pararec-
tal spaces to the CTV. Catheters were secured onto the surgical surface
with reabsorbable sutures, because catheter tunnelization is not possible in
that area. Single-plane implants were the preferred technique. Once the
implant was completed, a radioprotective flap was created with the greater
omentum using a technique previously described by Ho¨ckel [17].
Figure 2. Squamous cell carcinoma of the right border of the tongue
stage pT2N0 resected with close margins. The perioperative high-dose
rate brachytherapy implant covers the surgical bed in the tongue.
Figure 3. Recurrent clear cell carcinoma of the cervix involving the right
pelvic sidewall. The perioperative high-dose rate brachytherapy implant
covers the pelvic sidewall surface behind the external iliac vessels.
Figure 1. Treatment scheme. XRT, radiation therapy; HDR, high-dose rate brachytherapy; R0, R1, R2, type of surgical resection (see text); ChT, che-
motherapy; EBRT, external beam radiation therapy; MTD, minimum target dose, 4Gy/fraction; MCD, mean central dose, calculated at 5Gy/fraction.
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Sarcoma surgery. Single-plane implants were the preferred technique
(Figure 4). The longitudinal margins were added by setting the distal and
proximal ends of the catheters at 1.5–2 cm beyond the skin incision. If
necessary, gelfoam or muscle flaps no more than 5mm thick were inter-
posed between the catheter plane and radiosensitive structures. In all
cases, a sham plane reconstruction and wound closure was performed
before the completion of the implant to make sure that the catheters did
not overlap during closure. Once the implant was performed, the surgical
team proceeded with the closure or, if necessary, with the reconstruction
of the surgical defect with regional or microvascular free flaps. In abdomi-
nal or pelvic locations, an omentum or muscle flap was interposed
between the implant plane and the intra-abdominal contents.
Dosimetry guidelines
A CT scan for verification was performed during the second or third post-
operative day, once the patient was in stable condition and ready for trans-
portation. The CT study was transferred to the Radiation Treatment
Planning System (Abacus US module, version 3.55; Gammamed) for
three-dimensional dosimetry including definition of target(s) and organ(s)
at risk, source modeling, generation of dose volume histograms and evalu-
ation of plans. The treatment planning process followed the rules of the
Paris System with manual optimization for each of the CT slices.
Additional rules included that the CTV be encompassed by the 4Gy iso-
dose line, defined as the minimum tumor dose (MTD) isodose line as per
the ICRU recommendations [18]. An MTD to mean central dose ICRU
ratio of not less than 70% was accepted, provided that the volume encom-
passed by the 6Gy isodose (V150) was not greater than 50% of the volume
encompassed by the 4Gy isodose (V100). Automatic optimization algor-
ithms provided by the Treatment Planning System were not allowed. Once
the treatment plan was approved, it was transferred to the afterloader unit
control console where the dwell positions and treatment times were
double-checked by the radiation technologist.
Statistical analysis
Survival results were calculated using the Kaplan–Meier [19] method
from the date of surgery to the last follow-up visit, and differences were
evaluated with the log-rank test. Discrete variables were compared with
the Fisher’s exact test. Local failure was defined as the occurrence of
tumor regrowth in the area treated with brachytherapy or in an adjacent
region (i.e. recognition failure). Regional failure was defined as any other
failure in the anatomical area treated and distant failure was defined as
any other failure elsewhere.
Toxicity analysis
Acute toxicities were defined as those occurring from the date of surgery
to 60 days after the completion of the treatment. Toxicities were classified
as late if they occurred >60 days after the completion of the treatment.
Toxicities were documented according to the RTOG morbidity scoring
criteria. The scoring system was: 0 = no change; 1 =mild symptoms not
requiring medication; 2 =moderate symptoms requiring occasional medi-
cation; 3 = severe symptoms requiring frequent medications and/or a
minor surgical procedure; 4 = severe and persistent symptoms requiring a
major surgical procedure; and 5 = treatment-related death.
Preliminary results
One hundred and eighty-three patients have been included
during the study period from February 2000 to October 2004.
Patient characteristics are shown in Table 2. Data analysis is
based on 177 patients with at least 3 months of follow-up
after PHDRB.
The average dose deviation for the 177 patients analyzed
was 4.5% (Table 3). This was mainly due to a programmed
reduction in the EBRT dose in growing individuals [6], as
well as the need to decrease the overall target dose in some
paravertebral locations where the prescription dose would
Figure 4. Recurrent retroperitoneal soft tissue sarcoma. The perioperative
high-dose rate brachytherapy implant covers the right retroperitoneal sur-
face and the anterior aspect of the inferior vena cava.
Table 2. Patient population
n %
Number of patients 183 100.0
Diagnosis Head and neck 69 37.7
Tongue 23 12.6
Oropharynx 12 6.6
Major salivary glands 11 6.0
Floor of mouth 6 3.3
Other 17 9.3
Sarcomas 57 31.1
Soft tissue 49 26.8
Bone 8 4.4
Abdominopelvic 38 20.8
Gynecological cancer 23 12.6
Colorectal 15 8.2
Other 19 10.4
Disease status Primary disease 84 45.9
Recurrent Prior 99 54.1
Radiotherapy 57 31.1
No prior radiotherapy 42 23.0
Type of resection R0 36 19.7
R1 134 73.2
Close margins 67 36.6
Positive margins 67 36.6
R2 7 3.8
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have exceeded the spinal cord tolerance. In addition, the
PHDRB dose was reduced to the closest lower level, owing to
excessive toxicity in oropharyngeal and previously irradiated
pelvic tumors.
After a median follow-up of 19 months (range 3.5–54+) the
4-year local control rate was 82.5%. Local control rate corre-
lated with the quality of the surgical margin. Patients with
negative margins of resection (>_10mm) had a 4-year local
control rate of 97.1%, and patients with close and positive
margins had 4-year control rates of 83.8% and 76.8%, respect-
ively (P= 0.04). When compared by standardized dose [20],
we observed that patients receiving a total dose of <63Gy
(average 48.2±10.3Gy) had a control rate of 73.6% compared
with 91.6% (average 73.4±4Gy) for those patients receiving
>63Gy (P= 0.02) (Figure 5). This difference was even more
significant in the subgroup of patients with close margins
(<10mm), with a 4-year local control of 100% for the patients
who received a dose of >_63Gy versus 34.3% for those
patients receiving <63Gy (P= 0.0001). We were not able to
observe any dose–response relationship in those patients with
negative or positive margins. In the subgroup of patients with
negative margins receiving <63 versus >_63Gy, the 4-year
local control figures were 96.5% and 100%, respectively
(P= 0.678). Similarly, the 4-year local control rates for the
subgroup of patients with positive margins who received <63
versus >_63Gy were 82.1% and 75.2%, respectively
(P= 0.642).
The 4-year regional control rate was 72.5%. Patients with
negative, close and positive margins had a 4-year regional
control rates of 88.9%, 76.6% and 60.8%, respectively
(P = 0.0001). The 4-year distant control rate was 62.2%. The
corresponding figures for patients with negative, close and
positive margins were 79.3%, 74% and 43%, respectively
(P = 0.0001).
RTOG 4–5 complications that occurred in the anatomical
area treated (whether related to the delivery of PHDRB or
not) were seen in 27 patients (15.2%). Most were surgical in
nature. A detailed description of the toxicities observed is dis-
played in Table 4.
Conclusions
The 4-year local control results obtained with the different
PHDRB protocols described exceeds 80%. This is particularly
noteworthy taking into account that 54.1% of the patients
received PHDRB for recurrent tumors (31.1% after prior
Table 3. Protocol compliance
Category n Target dose (Gy) Actual dose (average) (Gy) Deviation (%)
Irradiation naı¨ve R0, unirradiated 31 62.9 63.7 +1
R1, unirradiated 87 72.3 68.2 6
Previously irradiated R0, prior XRT 5 37.3 37.3 None
R1, prior XRT 47 46.7 44.4 5
Total radiation doses equivalent to standard fractionation regimens delivered with 2Gy daily fractions and calculated with the linear quadratic formulation
[12] without time correction {i.e. BED=nd[1 + d/(a /b)]}.
XRT, radiation therapy.
Figure 5. Four-year local control rates by standardized dose.
Table 4. Toxicitya
Grades 1–3 Grade 4 Grade 5 Overall %
Bleeding 1 2 5 8 4.5
Bone damage 3 – – 3 1.7
Edema 2 – – 2 1.1
Graft failure 3 3 – 6 3.4
Nerve damage 22 – – 22 12.4
Seroma/abscess 6 – – 6 3.4
Soft tissue necrosis 3 4 – 7 4.0
Bowel damage 4 1 – 5 2.8
Fistula 6 5 – 11 6.2
Fibrosis 2 1 – 3 1.7
Thrombosis 1 – – 1 0.6
Ureteral damage 4 – – 4 2.3
Wound breakdown 12 4 – 16 9.0
Technical complications 2 1 – 3 1.7
aMore than one toxicity per patient.
Total radiation doses equivalent to standard fractionation regimens deliv-
ered with 2Gy daily fractions and calculated with the linear quadratic for-
mulation [12] without time correction {BED=nd[1 + d/(a /b)]}.
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irradiation) and 73.2% had surgical resections with close or
positive margins.
Patients with negative margins had the best 4-year local
control results (97.1%) despite a lower dose as per protocol.
Patients with close and positive margins had worse 4-year
local control results (83.8% and 76.8%, respectively)
(P= 0.04).
A dose–response relationship was observed in patients with
close margins with a cut-off level determined at a standardized
dose of 63Gy. This dose–response effect was not seen in
patients with negative or positive margins. Hence, it is uncer-
tain that escalating the PHDRB dose may improve the local
control results in patients with positive margins.
Most of the toxic events observed were surgical in nature.
Toxicity mainly related to PHDRB, alone or combined with
EBRT, included: four of the five cases of delayed fatal bleed-
ing (three previously irradiated pelvic tumors and one oro-
pharyngeal tumor); four cases of grade 4 soft tissue necrosis
(three in the oropharyngeal area); and 22 cases of neuritis,
mostly grade 1–2 and reversible. The toxic events observed
mandated a PHDRB dose reduction to the closest lower level
in oropharyngeal locations and in pelvic locations after prior
irradiation.
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